Benzinga | May 18, 2021 08:33AM EDT

Capricor To Present Preclinical Data For Exosome-mRNA Vaccine for SARS-CoV-2 International Society For Extracellular Vesicles Annual Meeting

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced that the Company will present data supporting its Exosome-Mediated mRNA Delivery approach against SARS-CoV-2 at the 10th Annual Meeting of the International Society for Extracellular Vesicles (ISEV), which is being held virtually May 18-21, 2021.

"As the COVID-19 pandemic continues to spread globally, the medical community anticipates additional challenges posed by new variant strains, as well as a likely need for different vaccine technologies," said Linda Marb?n, Ph.D., CEO, Capricor Therapeutics. "These data demonstrated that our exosome-based, multivalent mRNA vaccine elicited long-lasting cellular and humoral responses to both the N and S proteins. This data also supports our exosome platform technology which allows us to develop new, tailored and targeted therapeutic approaches to a variety of diseases and disorders."